Jianmin Fang, RemeGen CEO (RemeGen)

ADC ex­perts at Seagen find a $2.6B HER2 gem in Chi­na that they think can go where En­her­tu, Kad­cy­la can't

If a record IPO wasn’t enough to put Re­meGen on the map, per­haps a deal with Seagen — sport­ing $200 mil­lion in cash — might.

At the cen­ter of the li­cens­ing pact is disi­ta­m­ab ve­dotin, an an­ti-HER2 an­ti­body-drug con­ju­gate that will slide di­rect­ly in­to Seagen’s pipeline, ex­cept in cer­tain Asian coun­tries where Chi­na-based Re­meGen will be keep­ing de­vel­op­ment and com­mer­cial­iza­tion rights.

The fel­low ADC spe­cial­ists have been fol­low­ing each oth­er for quite a while, Re­meGen CEO Jian­min Fang tells me, as his trans-Pa­cif­ic team lever­aged Seagen’s link­er tech­nol­o­gy and kept it post­ed on clin­i­cal da­ta. It just hap­pens to be the right time to pull the trig­ger.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.